Citations (1)
Keep up to date with the latest research on this topic with citation updates for this article.
Hematology
Volume 26, 2021 - Issue 1
Articles
3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma
Chor Sang Chima Department of Medicine, Queen Mary Hospital, University of Hong Kong, Pok Fu Lam, Hong KongCorrespondence[email protected]
https://orcid.org/0000-0003-2427-915X
https://orcid.org/0000-0003-2427-915X, Shaji Kumarb Division of Hematology, Mayo Clinic, Rochester, MN, USAhttps://orcid.org/0000-0001-5392-9284
https://orcid.org/0000-0001-5392-9284, , Cheong Ngaia Department of Medicine, Queen Mary Hospital, University of Hong Kong, Pok Fu Lam, Hong Konghttps://orcid.org/0000-0002-6438-2170
https://orcid.org/0000-0002-6438-2170 & Yok Lam Kwonga Department of Medicine, Queen Mary Hospital, University of Hong Kong, Pok Fu Lam, Hong Konghttps://orcid.org/0000-0001-8156-6978
https://orcid.org/0000-0001-8156-6978